Systemic administration of interleukin-2 in humans.

  title={Systemic administration of interleukin-2 in humans.},
  author={Michael T Lotze and Richard J. Robb and Susan O. Sharrow and L W Frana and Steven A Rosenberg},
  journal={Journal of biological response modifiers},
  volume={3 5},
Twelve patients were treated in a Phase I trial of purified human interleukin-2 (IL-2) derived from the JURKAT cell line (E.I. duPont Corp., Glenolden, PA, U.S.A.). The serum half-life, toxicity, and in vivo immunologic effects of IL-2 were studied in patients with cancer unresponsive to standard therapy and in patients with acquired immunodeficiency syndrome (AIDS). Patients received 0.25, 2.5, or 25 micrograms/kg IL-2 by bolus or 24-h continuous infusion on a weekly basis for 4 weeks. The… CONTINUE READING
26 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…